Home Study Details

    Program Type

    Home Study Webcast


    1.5 Contact Hour(s)

    Release Date

    Wednesday, October 26, 2022

    Offline Date

    Thursday, October 26, 2023

    ACPE Expiration Date

    Thursday, October 26, 2023

    Target Audience




    • Overview

      Activity attendees will gain an understanding of the role of the DNA damage response (DDR) pathway in solid tumor tumorigenesis and the latest guidelines and importance of genetic testing/counseling and related treatment recommendations; then they will be guided through an appraisal of current and emerging evidence for PARP inhibitors for solid tumor management. An expert-led discussion in transcending disparities in cancer care and improving equitable access will follow, as will a review of PARP inhibitor toxicity profiles and how to effectively anticipate, prevent, and manage adverse events that may arise. After the didactic portion of the presentation, an interactive case-based presentation will provide attendees an opportunity to apply what they have learned, with an emphasis on appropriate treatment selection, toxicity management, mitigation of modifiable health disparities, and promotion of patient adherence to oral oncolytic therapy.


      • Slide Document :   AMCP Nexus - Final Handout.pdf

      Financial Support By

      AstraZeneca and Merck
    • Pharmacist

      Appraise current expert consensus guideline recommendations for managing solid tumor malignancies with PARP inhibitors, including evidence-based approaches for anticipating, mitigating, and managing adverse events
      Recognize healthcare disparities that result in inequitable access and identify approaches for overcoming these obstacles and improving outcomes for all patients
      Evaluate the crucial importance of genetic testing/counseling when considering PARP inhibitor therapy for patients with solid tumors
      Use a case-based approach to develop practical strategies for appropriate treatment selection, toxicity management, mitigation of healthcare disparities and inequitable access to care, and promotion of patient adherence to PARP inhibitors and other oral oncolytics, with the express goal of improving outcomes across the solid tumor landscape
      Review emerging PARP inhibitor clinical trial data in both the treatment and maintenance settings for solid tumors, and discuss how these agents continue to galvanize change across the disease management continuum
    • Activity Type


      CE Broker


      Universal Activity Number

      Pharmacist 0798-9999-22-277-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones

    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Firefox 3.0.3 or higher

    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).